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Studies to enhance our understanding of the triple-
negative breast cancers (TNBC) spectrum are needed to 
improve our current management, and ultimately out-
comes, of patients diagnosed with TNBC. In the present 
issue, Keam and colleagues explored the expression of 
the proliferation-related marker Ki-67 in 105 patients 
with TNBC treated with neoadjuvant chemotherapy [1]. 
Th   eir results suggest two subgroups of TNBC might exist 
by Ki-67 expression, each with diﬀ  erential response and 
prognosis following neoadjuvant chemotherapy.
TNBC – deﬁ   ned as estrogen receptor, progesterone 
receptor and human epidermal growth factor receptor 
type 2 (HER2) negativity – are heterogeneous in terms of 
biology, prog  nosis and response to treatment [2-7]. 
TNBC are asso  ciated with younger age at diagnosis [8] 
and with poorer outcomes compared with non-TNBC [9-
12]. Patients with TNBC, however, have increased rates 
of patho logical complete response (pCR) after neoadjuvant 
chemo therapy compared with other subtypes [9,10]. Th  e 
presence or absence of residual disease after preoperative 
chemo  therapy has been found to be a strong predictor of 
survival in TNBC. Liedtke and colleagues found 3-year 
survival of TNBC patients with and without residual 
disease after neoadjuvant chemotherapy to be 68% and 
94%, respectively [10]. Th   e increased pCR rates but worse 
survival observed in TNBC – the triple-negative paradox 
[9] – appears to be driven by higher relapse rates among 
those patients whose tumors are not eradicated by 
chemotherapy.
Among 105 patients with TNBC treated with neo-
adjuvant chemotherapy, Keam and colleagues identiﬁ  ed 
26.7% TNBC with low Ki-67 (deﬁ  ned as staining in <10% 
of cells) despite most cases being high grade [1]. 
Secondly, they evaluated the association of Ki-67 with 
pCR and survival after only three cycles of preoperative 
chemotherapy (doxorubicin/docetaxel), which may explain 
the lower rate of pCR (13.3%) compared with previous 
studies [10,13]. All TNBC patients achieving pCR were 
identiﬁ  ed within the high Ki-67 group (18.2%), and they 
showed improved relapse-free survival and overall 
survival compared with those TNBC patients with 
residual disease and high Ki-67. Conversely, none of the 
TNBC patients with low Ki-67 achieved pCR; survival 
was similar to those with high Ki-67 who achieved pCR.
Th   e data presented herein suggest that two subgroups 
of TNBC might exist based on Ki-67 with diﬀ  erential 
response and prognosis after preoperative chemotherapy. 
More importantly, it seems that only within the high 
Ki-67 group will pCR possibly be an appropriate surro-
gate for survival outcome. It is important to point out 
that TNBC patients with residual disease, even those 
with low Ki-67, still have 5-year relapse-free survival of 
roughly 75%. From a clinical perspective, these patients 
are still at a substantial risk for relapse. Although this 
study raises important questions, further validation of 
Ki-67 in independent datasets and optimal cutoﬀ   values 
in TNBC are needed [14].
Previous studies have shown that TNBC are not a 
single disease process [3-7,15-17]. Th  ese studies have 
used various markers evaluated by diﬀ  erent assays based 
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status (Figure 1). Global gene expression studies illustrate 
two main intrinsic subtypes of breast cancer (basal-like 
and claudin-low) within TNBC – although the basal-like 
subtype predominates (50 to 70%) [4], with high rates of 
p53 mutations [18]. Th  e recently characterized claudin-
low subtype is mostly composed of high-grade invasive 
ductal carcinomas with a high frequency of metaplastic 
and medullary diﬀ   erentiation [3,4]. Compared with 
basal-like tumors, claudin-low tumors are enriched for 
mesenchymal and stem cell-like biological processes 
[3,4]. Claudin-low tumors show lower expression of 
proliferation-related genes, including MKI67 [3]. While 
survival diﬀ  erences have not been observed between the 
basal-like and claudin-low subtypes, claudin-low tumors 
showed lower rates of pCR (versus basal-like) after pre-
operative anthracyline/taxane-based chemotherapy in a 
cohort of 133 patients [3]. Evidence for other subtypes 
within TNBC, including mesenchymal-related, pro-
liferation-related and immune-related subsets, with 
varying prognoses have also been suggested by other 
investigators [17].
Studies based on basal immunohistochemical markers 
(epidermal growth factor receptor type 1 (EGFR), cyto-
keratin 5/6) have shown that at least two subgroups of 
TNBC exist [5,6]. Nielsen and colleagues, using a panel of 
basal-like tumors (deﬁ  ned by gene expression proﬁ  ling), 
observed that four immunohistochemical markers (estro-
gen receptor-negative, HER2-negative, and/or EGFR-
positive or cytokeratin 5/6-positive) could accurately 
identify basal-like tumors with high speciﬁ  city [5]. In a 
subsequent study, Cheang and colleagues observed 
superior prognostic value of the basal-like immuno-
histochemical deﬁ   nition (core basal) using these four 
biomarkers (plus proges  terone receptor negativity) than 
when using the standard estrogen receptor-negative/
proges  terone receptor-negative/HER2-negative deﬁ  ni-
tion [6]. Th   e other triple-negative group, deﬁ  ned as nega-
tivity for all ﬁ   ve biomarkers (ﬁ  ve-marker  negative 
phenotype), showed improvement in breast cancer-
speciﬁ  c survival compared with the core basal group. It is 
currently unknown whether the ﬁ  ve-marker  negative 
phenotype group is associated with the claudin-low 
tumors and/or the low Ki-67 tumors. Additional studies 
to determine the relationship between ﬁ  ve-marker nega-
tive phenotype tumors, claudin-low tumors and low 
Ki-67 tumors, and possible overlap within TNBC, are 
certainly worthy of exploration.
Th  e association between BRCA1  mutations and the 
development of TNBC is well established [16]. A recent 
report suggests that BRCA1 mutations occur in close to 
20% of sporadic TNBC and are associated with im  proved 
prognosis [15]. It is currently unknown whether BRCA1-
mutated tumors more closely resemble claudin-low or 
basal-like TNBC. Moreover, tumors arising in BRCA1 
mutation carriers illustrate sensitivity to poly-(ADP)-
ribose polymerase inhibitors, thus suggesting that 
mutated  BRCA1 within TNBC could be predictive of 
response to this novel class of agents [19,20].
TNBC are heterogeneous and there are probably 
clinically-relevant subtypes within this subset of breast 
cancer. A remain  ing clinical question is which patient 
post-neoadjuvant chemotherapy requires additional 
systemic therapy to optimize the outcome? Th  e  relation-
ship(s) of the various TNBC subgroups identiﬁ  ed  by 
either cytokeratin 5/6–EGFR, Ki-67 or BRCA1 status and 
molecular subtyping by gene expression to help answer 
this question certainly warrant further investi  gation. Co-
ordi  nat  ing the many deﬁ   nitions under the TNBC 
umbrella to use each of the available biomarkers, either 
individually or in combination, to stratify TNBC into 
clinically relevant subgroups should be our ultimate goal.
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